Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109367 | 0.84 | DRD2 (0.42) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3118533 | 0.82 | DRD2 (0.43) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3115698 | 0.81 | DRD2 (0.39) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3109607 | 0.81 | DRD2 (0.38) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3853965 | 0.80 | OPRM1 (0.43) | DRD2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL3113243 | 0.78 | SIGMAR1 (0.40) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3119581 | 0.78 | OPRM1 (0.45) | DRD2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL3109230 | 0.78 | CYP2D6 (0.41) | DRD2OPRM1USP2ALDH1A1HPGD | |
| SCHEMBL3111159 | 0.78 | OPRL1 (0.54) | USP2ALDH1A1HPGDOPRL1GAA | |
| SCHEMBL3111280 | 0.76 | OPRM1 (0.41) | DRD2OPRM1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | claimed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | claimed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | claimed |
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | DRD2 9/4885OPRM1 364/4885USP2 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.